Published in
Elsevier, The Lancet Oncology, 7(20), p. 961-971, 2019
DOI: 10.1016/s1470-2045(19)30331-6
Links
Tools
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
Journal article published in 2019 by
Georgina V. Long,
Robyn P. M. Saw,
Serigne Lo,
Omgo E. Nieweg,
Kerwin F. Shannon,
Maria Gonzalez,
Alexander Guminski,
Jenny H. Lee,
Hansol Lee,
Peter M. Ferguson 
,
Robert V. Rawson,
James S. Wilmott,
John F. Thompson,
Richard F. Kefford ,
Sydney Ch'ng
and other authors.
,
Robert V. Rawson,
James S. Wilmott,
John F. Thompson,
Richard F. Kefford ,
Sydney Ch'ng
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 